HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Givaudan

This article was originally published in The Rose Sheet

Executive Summary

Swiss fragrance and flavors company recently introduced Cosmone, a "novel" fragrance ingredient described as an "intensely rich, powerful and elegant musk," firm announces in first quarter earnings release. Slow retail sales during the 2008 holiday season in North America and Europe led to destocking of fine fragrances in the quarter, resulting in a decline in total fragrance sales of 10.4 percent (5.4 percent in local currencies) to $382.3 million (CHF1=$.87), company reports. Lack of consumer confidence and reduced travel is likely to impact fine fragrance sales throughout 2009, firm notes. Net sales for the period declined 7.3 percent (2.6 percent in local currencies) to $850.7 million, Givaudan reports. Despite first quarter performance, Givaudan expects its total fragrance and flavors businesses will outgrow the underlying market

You may also be interested in...



Beauty Market News: China Cosmetics Regulations Modernized, Florida Stops Local Oxybenzone Bans, More

L’Oreal acquires Thayers Natural Remedies; Unilever, L’Oreal remove ‘whitening,’ ‘fair’ from labels; China finalizes modernization of cosmetics regulations; and Florida governor signs law preventing local bans on oxybenzone.

Compounded Hormone Therapies Lack Evidence Of Safety And Effectiveness, Say National Academies

The US Food and Drug Administration should require that outsourcing facilities collect bioavailability data for compounded bioidentical hormone replacement therapy products, while compounding pharmacies should be required to report adverse events to state pharmacy boards and the FDA. Such actions would help resolve some of the safety concerns for these products, says a 1 July report from the National Academy of Sciences, Engineering and Medicine.

Biogen/Eisai Hit ‘Send’ On High Stakes BLA For Aducanumab In Alzheimer’s Disease

Some analysts see a 50-50 chance of US FDA approval despite the controversial dataset for the anti-amyloid antibody, but at least one expects an eventual CRL requesting a third Phase III trial.

UsernamePublicRestriction

Register

LL1132972

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel